Curovir AB
Privately-held Swedish biopharmaceutical company focused on discovery and development of broad‑spectrum small‑molecule antivirals for enterovirus infections and respiratory syncytial virus (RSV). Operates as a virtual, collaboration-driven organization that advances candidate compounds through preclinical studies and early clinical trials, and maintains an active patent portfolio.
Industries
Nr. of Employees
small (1-50)
Patents
2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
US-12319696-B2
View Details
2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
US-12319696-B2
View DetailsProducts
CUR-N399
A host‑targeting small‑molecule antiviral that inhibits the PI4KB enzyme to prevent enterovirus replication; displays potent activity in the nanomolar range across multiple enterovirus subgroups and in vitro activity versus RSV; selected for clinical development.
Pleconaril (evaluational use)
A direct‑acting antiviral historically evaluated for rhinovirus infections; being evaluated by the organization (via collaboration) in combination with another antiviral in investigator‑initiated trials for potential effects on type 1 diabetes progression.
CUR-N399
A host‑targeting small‑molecule antiviral that inhibits the PI4KB enzyme to prevent enterovirus replication; displays potent activity in the nanomolar range across multiple enterovirus subgroups and in vitro activity versus RSV; selected for clinical development.
Pleconaril (evaluational use)
A direct‑acting antiviral historically evaluated for rhinovirus infections; being evaluated by the organization (via collaboration) in combination with another antiviral in investigator‑initiated trials for potential effects on type 1 diabetes progression.
Services
Providing antiviral compounds and scientific collaboration to academic investigators and clinical trial sponsors; managing outsourced preclinical and clinical development tasks.
Providing antiviral compounds and scientific collaboration to academic investigators and clinical trial sponsors; managing outsourced preclinical and clinical development tasks.
Expertise Areas
- Antiviral drug discovery
- Host‑targeting antiviral strategies
- Medicinal chemistry and small‑molecule optimization
- Preclinical efficacy and safety testing
Key Technologies
- PI4KB‑targeted small‑molecule inhibitors
- Host‑targeting antiviral (HTA) approach
- In‑vitro antiviral screening assays
- Preclinical infection models
News & Updates
Initial results from the Phase II investigator‑initiated trial evaluating a combination of pleconaril and ribavirin in newly diagnosed children with type 1 diabetes were published in Nature Medicine.
First two subjects were dosed in the company's second Phase I clinical trial of CUR‑N399.
Company announced successful completion of its first clinical trial with CUR‑N399.
First two healthy volunteers were dosed in the first‑in‑human Phase I trial evaluating safety and pharmacokinetics of single and repeated ascending doses, including an elderly cohort.
Received collaborative funding for development of a formulation for pediatric use and confirmation of antiviral effect against RSV in addition to enterovirus activity.
Received funding to finalize preclinical toxicology studies and support a first‑in‑human Phase I clinical trial.
Initial results from the Phase II investigator‑initiated trial evaluating a combination of pleconaril and ribavirin in newly diagnosed children with type 1 diabetes were published in Nature Medicine.
First two subjects were dosed in the company's second Phase I clinical trial of CUR‑N399.
Company announced successful completion of its first clinical trial with CUR‑N399.
First two healthy volunteers were dosed in the first‑in‑human Phase I trial evaluating safety and pharmacokinetics of single and repeated ascending doses, including an elderly cohort.
Received collaborative funding for development of a formulation for pediatric use and confirmation of antiviral effect against RSV in addition to enterovirus activity.
Received funding to finalize preclinical toxicology studies and support a first‑in‑human Phase I clinical trial.